Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Investor Day (May 2022)
39 slides from Fisher & Paykel Healthcare's investor day presentation, May 26, 2022
Slide 1: News Release: Investor Day presentation
News Release STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) Fisher & Paykel Healthcare provides Investor Day presentation For personal use only Auckland, New Zealand, 26 May 2022 Fisher & Paykel Healthcare Corporation Limited attaches a copy of its presentation to analysts and investors
Slide 2: Better Products: An R&D Overview
For personal use only Better Products: An R&D Overview Andrew Somervell – Vice President Products and Technology
Slide 3: Agenda
Fisher & Paykel Healthcare Investor Day 2022 Agenda For personal use only General Manager - Respiratory Humidification & 10:00am Welcome Andy Niccol & Vandna Patel Product Development Engineer 10:05am Our Aspiration Lewis Gradon & Lyndal York Managing Director / CEO & CFO Better Products: an R&D 10:
Slide 4: Our aspiration
For personal use only Our aspiration Lewis Gradon – Managing Director / CEO Lyndal York - CFO
Slide 5: Our aspiration – prior to COVID-19
Our aspiration – prior to COVID-19 OUR ASPIRATION: For personal use only Sustainably DOUBLING our constant currency revenue every 5-6 years.
Slide 6: Our aspiration - now
Our aspiration - now OUR ASPIRATION: For personal use only Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s lo
Slide 7: Our aspiration - now
Our aspiration - now OUR ASPIRATION: For personal use only Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s lo
Slide 8: Our aspiration - now
Our aspiration - now OUR ASPIRATION: For personal use only Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s lo
Slide 9: Our aspiration - now
Our aspiration - now OUR ASPIRATION: For personal use only Sustainably DOUBLING our constant currency revenue every 5-6 years. COVID-19 has accelerated placement of hospital hardware and given us the opportunity to advance our longer-term plans. The image above is an illustration of the company’s lo
Slide 10: Long term margin targets
Long term margin targets For personal use only GROSS MARGIN OPERATING (EBIT) MARGIN • Long term gross margin and 70% 40% operating margin targets 35% 60% remain unchanged 30% 50% • Freight rates expected to 25% remain elevated in the near 40% term 20% 30% 15% Accelerated investment in: 20% 10% • R&D
Slide 11: Expansion of R&D and manufacturing facilities
Expansion of R&D and manufacturing facilities For personal use only ~$700m capital expenditure over about five years. This includes: New Zealand • Completion of building 5 • Acquisition of second R&D and manufacturing campus in New Zealand Tijuana, Mexico • Completion of a third manufacturing facili
Slide 12: Better Products: An R&D Overview
For personal use only Better Products: An R&D Overview Andrew Somervell – Vice President Products and Technology
Slide 13: Better Products: Enabling Clinical Practice Change
Better Products: Enabling Clinical Practice Change Products that: For personal use only Improve care Drive sustainable and outcomes profitable growth Improve patient Enable treatment outcomes of more patients Improve the Unique delivery of care technologies that deliver customer Lower overall cost v
Slide 14: A Patient Focused Culture
A Patient Focused Culture • Underlying philosophy of doing what For personal use only is best for patients − Aligns with long-term needs of all caregivers • Patient care is complex. Complexity provides opportunity • Deep, broad understanding of patient care leads to new insights and solutions • Pati
Slide 15: Patient Focused Teams: In-depth Knowledge
Patient Focused Teams: In-depth Knowledge For personal use only
Slide 16: Enabling our Product Teams
Enabling our Product Teams For personal use only • Our people: attracting and growing top talent • First-hand access to user environments • Engaging world-leading expertise • Leading prototyping and testing facilities • Co-locating R&D and manufacturing
Slide 17: Airvo
For personal use only Airvo 3 Chris Crone – General Manager Sam Frame – Marketing Manager
Slide 18: Airvo
Airvo 3 For personal use only Designed to facilitate treatment: • of more patients • in more hospital areas • by more types of clinicians
Slide 19: Integrated battery
Integrated battery For personal use only Current challenge: • Nasal high flow requires a continuous power supply • Continuity of therapy is key Airvo 3 facilitates: • Transfer for diagnostics • Earlier initiation, e.g. prior to admission
Slide 20: Standardised tube kits and interfaces
Standardised tube kits and interfaces For personal use only Current challenge: • Storage and training burden for new equipment • Treating a wider range of patients Airvo 3 facilitates: • A lower barrier to fleet expansion • Treatment of new patients requiring smaller interfaces
Slide 21: Option for faster reprocessing
Option for faster reprocessing For personal use only Current challenge: • Downtime of equipment • Differing preference of reprocessing Airvo 3 facilitates: • Greater time treating patients • Flexible options for reprocessing
Slide 22: Clinical user menu and settings
Clinical user menu and settings For personal use only Current challenge: • Distance between decision makers and patients • Adherence to hospital protocols Airvo 3 facilitates: • Personalised clinical parameters • Alignment between default settings and protocols
Slide 23: OptiO2 - closed loop oxygen control
OptiO2 - closed loop oxygen control For personal use only Current challenge: • Oxygen can be under or over delivered • Difficult to keep patients within their target range Airvo 3 facilitates: • Use in areas where control matters most • A patient-specific approach
Slide 24: Surgical Humidification: Open Abdominal Surgery
For personal use only Surgical Humidification Open Abdominal Surgery Winston Fong - Vice President Surgical Technologies
Slide 25: Intro – Laparotomy
Intro – Laparotomy For personal use only • Patient and open surgical site is exposed to ambient air during laparotomy surgery • Very different to natural physiological state (warm and wet) • Causes evaporation which results in loss of heat and moisture from patient
Slide 26: Clinical problems
Clinical problems Hypothermia Surgical site infection For personal use only Tissue / Cell damage
Slide 27: SI400 flow visualisation
SI400 flow visualisation For personal use only
Slide 28: Product: SI400 Humidified Gas Diffuser
Product For personal use only SI400 Humidified Gas Diffuser Flexible tube Adhesive Backing Mouldable foam head Sterile and Single use Low profile
Slide 29: How could warm, humidified CO2 benefit the patient?
How could warm, humidified CO2 benefit the patient? For personal use only • Improves temperature • Provides humidity • Reduces risk of SSI CO2 • Improves local wound temperature • Increases tissue oxygenation and perfusion Warm Humidity • Reduces morphological mesothelial damage
Slide 30: Optiflow Anesthesia
For personal use only Optiflow Anesthesia Winston Fong - Vice President Surgical Technologies
Slide 31: Optiflow nasal high flow therapy
Optiflow nasal high flow therapy For personal use only Mechanisms of action Respiratory Spontaneously breathing patients support with or at risk of respiratory compromise Reduction of Dynamic positive dead airway space pressure Airway Patient hydration comfort Supplemental oxygen (if required)
Slide 32: What is anesthesia?
What is anesthesia? For personal use only Analgesia Management of pain Amnesia Controlled state of unconsciousness and loss of memory Paralysis Management of patient movement
Slide 33: General Anesthesia – Clinical complications
General Anesthesia – Clinical complications For personal use only • Anesthetic agents − Neuro muscular blockade → apnoeic − Loss of muscle tone, airway collapse, atelectasis • Complications include − Airway damage causing: swelling → airway closure − Intubation failure − Desaturation causing anesthe
Slide 34: Sedation – Clinical complications
Sedation – Clinical complications • Anesthetic agents For personal use only − Represses breathing − Causes atelectasis • Complications include − Desaturation: 26-85% of GI Endoscopy cases desaturate1 − Disrupts procedure − Surgery delays − Patient risk/dissatisfaction 1 Nay MA et al. High-flow nasal
Slide 35: Optiflow Switch
Optiflow SwitchTM For personal use only Enables delivery of humidified oxygen in the peri-anesthesia environment User can Switch between bag mask ventilation and Optiflow without needing to remove the nasal interface Reduces the number of steps required to bag mask ventilate a patient vs standard Op
Slide 36: Optiflow Trace
Optiflow TraceTM For personal use only Sampling of exhaled Secure connection gas from either nose with standard CO2 or mouth* sampling lines Continuous sampling of exhaled CO2 while using Optiflow nasal high flow for oxygenation* *Attention: this applies for flow rates between 5-50L/min.
Slide 37: Systematic and growing clinical evidence
Systematic and growing clinical evidence For personal use only Hung, 2022 GI endoscopy – demonstrated the efficacy of high flow nasal oxygenation for reducing the risk of hypoxemia in patients under sedation. Guideline 2022 Su, 2022 Bronchoscopy - HFNC may provide consistent Systematic review oxygen
Slide 38: Summary
Summary • Ongoing innovation For personal use only • Strong and continually growing clinical evidence • Change in clinical practice • Sustainable profitable growth • Extending the use of Optiflow into anesthesia practice
Slide 39: Better Products: An R&D Overview
For personal use only Better Products: An R&D Overview Andrew Somervell – Vice President Products and Technology